HC Wainwright Reaffirms Buy Rating for Sutro Biopharma (NASDAQ:STRO)

Sutro Biopharma (NASDAQ:STRO)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 344.44% from the company’s current price. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2025 earnings at ($0.87) EPS and Q4 2025 earnings at ($0.96) EPS.

Other analysts also recently issued research reports about the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday, October 11th. Truist Financial lowered their target price on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Finally, JMP Securities reissued a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a report on Monday, September 16th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $12.14.

Sutro Biopharma Trading Down 1.8 %

Shares of STRO opened at $2.70 on Monday. Sutro Biopharma has a twelve month low of $2.13 and a twelve month high of $6.13. The stock’s fifty day simple moving average is $3.68 and its 200 day simple moving average is $3.82. The firm has a market capitalization of $222.64 million, a P/E ratio of -1.68 and a beta of 1.17.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in STRO. Point72 Asset Management L.P. boosted its position in shares of Sutro Biopharma by 1,606.1% in the second quarter. Point72 Asset Management L.P. now owns 4,447,634 shares of the company’s stock worth $13,032,000 after buying an additional 4,186,938 shares during the period. Bank of Montreal Can acquired a new stake in Sutro Biopharma during the third quarter valued at $2,852,000. Jacobs Levy Equity Management Inc. increased its position in Sutro Biopharma by 214.3% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,069,522 shares of the company’s stock worth $6,043,000 after purchasing an additional 729,239 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Sutro Biopharma in the 3rd quarter valued at approximately $1,512,000. Finally, Acadian Asset Management LLC lifted its stake in Sutro Biopharma by 30.8% in the second quarter. Acadian Asset Management LLC now owns 1,574,958 shares of the company’s stock valued at $4,613,000 after acquiring an additional 370,705 shares during the last quarter. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.